{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:29:28Z","timestamp":1788845368636,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza","award":["24\/12 IRP"],"award-info":[{"award-number":["24\/12 IRP"]}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["23109"],"award-info":[{"award-number":["23109"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","award":["20IN28"],"award-info":[{"award-number":["20IN28"]}],"id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007479","name":"Fondazione Cassa di Risparmio di Padova e Rovigo","doi-asserted-by":"publisher","award":["20\/16 FCR"],"award-info":[{"award-number":["20\/16 FCR"]}],"id":[{"id":"10.13039\/100007479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"University of Padova","doi-asserted-by":"crossref","award":["SID grant"],"award-info":[{"award-number":["SID grant"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["15010"],"award-info":[{"award-number":["15010"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-026-02265-3","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:45:49Z","timestamp":1772210749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TrkA activation sustains chemotherapy resistance in chemotolerant medulloblastoma cells"],"prefix":"10.1186","volume":"14","author":[{"given":"Lorenzo","family":"Manfreda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bortolozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mariotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampietro","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Persano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rampazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2265_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","volume":"24","author":"EJ Huang","year":"2001","unstructured":"Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677\u2013736","journal-title":"Annu Rev Neurosci"},{"key":"2265_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mcn.2018.03.013","volume":"91","author":"E Scott-Solomon","year":"2018","unstructured":"Scott-Solomon E, Kuruvilla R (2018) Mechanisms of neurotrophin trafficking via Trk receptors. Mol Cell Neurosci 91:25\u201333","journal-title":"Mol Cell Neurosci"},{"issue":"4","key":"2265_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrn1078","volume":"4","author":"MV Chao","year":"2003","unstructured":"Chao MV (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4(4):299\u2013309","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"2265_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/cancers12092542","volume":"12","author":"A de Thomaz","year":"2020","unstructured":"Thomaz A, Jaeger M, Brunetto AL, Brunetto AT, Gregianin L, de Farias CB et al (2020) Neurotrophin signal medulloblastoma. Cancers (Basel) 12(9):2542","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2265_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","volume":"169","author":"A Nakagawara","year":"2001","unstructured":"Nakagawara A (2001) Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169(2):107\u2013114","journal-title":"Cancer Lett"},{"issue":"5","key":"2265_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/0092-8674(94)90048-5","volume":"77","author":"WD Snider","year":"1994","unstructured":"Snider WD (1994) Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 77(5):627\u2013638","journal-title":"Cell"},{"issue":"1","key":"2265_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13046-016-0395-y","volume":"35","author":"L Aloe","year":"2016","unstructured":"Aloe L, Rocco ML, Balzamino BO, Micera A (2016) Nerve growth factor: role in growth, differentiation and controlling cancer cell development. J Exp Clin Cancer Res 35(1):116","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2265_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00280-009-1110-x","volume":"65","author":"M Bassili","year":"2010","unstructured":"Bassili M, Birman E, Schor NF, Saragovi HU (2010) Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemother Pharmacol 65(6):1047\u20131056","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2265_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-019-05506-3","volume":"179","author":"K Kyker-Snowman","year":"2020","unstructured":"Kyker-Snowman K, Hughes RM, Yankaskas CL, Cravero K, Karthikeyan S, Button B et al (2020) TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Res Treat 179(3):631\u2013642","journal-title":"Breast Cancer Res Treat"},{"issue":"154","key":"2265_CR10","first-page":"195","volume":"28","author":"AT Regua","year":"2019","unstructured":"Regua AT, Doheny D, Arrigo A, Lo HW (2019) Trk receptor tyrosine kinases in metastasis and cancer therapy. Discov Med 28(154):195\u2013203","journal-title":"Discov Med"},{"issue":"1","key":"2265_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0092-8674(91)90419-Y","volume":"65","author":"R Klein","year":"1991","unstructured":"Klein R, Jing SQ, Nanduri V, O\u2019Rourke E, Barbacid M (1991) The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 65(1):189\u2013197","journal-title":"Cell"},{"issue":"5892","key":"2265_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/300539a0","volume":"300","author":"S Pulciani","year":"1982","unstructured":"Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M (1982) Oncogenes in solid human tumours. Nature 300(5892):539\u2013542","journal-title":"Nature"},{"issue":"5","key":"2265_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/dneu.20767","volume":"70","author":"LC Schecterson","year":"2010","unstructured":"Schecterson LC, Bothwell M (2010) Neurotrophin receptors: old friends with new partners. Dev Neurobiol 70(5):332\u2013338","journal-title":"Dev Neurobiol"},{"issue":"12","key":"2265_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15(12):731\u2013747","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2265_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40263-024-01121-z","volume":"38","author":"DC Moreira","year":"2024","unstructured":"Moreira DC, Mikkelsen M, Robinson GW (2024) Current landscape of NTRK inhibition for pediatric CNS tumors. CNS Drugs 38(11):841\u2013849","journal-title":"CNS Drugs"},{"issue":"Suppl 5","key":"2265_CR16","first-page":"1","volume":"22","author":"DS Hong","year":"2024","unstructured":"Hong DS, Drilon A, Wirth LJ (2024) Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Clin Adv Hematol Oncol 22(Suppl 5):1\u201320","journal-title":"Clin Adv Hematol Oncol"},{"key":"2265_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","volume":"173","author":"YB Khotskaya","year":"2017","unstructured":"Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS (2017) Targeting TRK family proteins in cancer. Pharmacol Ther 173:58\u201366","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2265_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","volume":"5","author":"PA Northcott","year":"2019","unstructured":"Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC et al (2019) Medulloblastoma. Nat Rev Dis Primers 5(1):11","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2265_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/(SICI)1097-4547(19970901)49:5<522::AID-JNR2>3.0.CO;2-D","volume":"49","author":"TT Chou","year":"1997","unstructured":"Chou TT, Trojanowski JQ, Lee VM (1997) Neurotrophin signal transduction in medulloblastoma. J Neurosci Res 49(5):522\u2013527","journal-title":"J Neurosci Res"},{"issue":"3","key":"2265_CR20","first-page":"929","volume":"148","author":"K Washiyama","year":"1996","unstructured":"Washiyama K, Muragaki Y, Rorke LB, Lee VM, Feinstein SC, Radeke MJ et al (1996) Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system. Am J Pathol 148(3):929\u2013940","journal-title":"Am J Pathol"},{"issue":"5","key":"2265_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/dneu.20769","volume":"70","author":"L Harel","year":"2010","unstructured":"Harel L, Costa B, Fainzilber M (2010) On the death Trk. Dev Neurobiol 70(5):298\u2013303","journal-title":"Dev Neurobiol"},{"issue":"6","key":"2265_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B et al (2017) Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31(6):737\u2013754e6","journal-title":"Cancer Cell"},{"issue":"6","key":"2265_CR23","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13311-022-01273-0","volume":"19","author":"MA Lazow","year":"2022","unstructured":"Lazow MA, Palmer JD, Fouladi M, Salloum R (2022) Medulloblastoma in the modern era: review of contemporary trials, molecular advances, and updates in management. Neurotherapeutics 19(6):1733\u20131751","journal-title":"Neurotherapeutics"},{"key":"2265_CR24","doi-asserted-by":"publisher","first-page":"108673","DOI":"10.1016\/j.pharmthera.2024.108673","volume":"260","author":"K Peterson","year":"2024","unstructured":"Peterson K, Turos-Cabal M, Salvador AD, Palomo-Caturla I, Howell AJ, Vieira ME et al (2024) Mechanistic insights into medulloblastoma relapse. Pharmacol Ther 260:108673","journal-title":"Pharmacol Ther"},{"issue":"34","key":"2265_CR25","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2016.67.2428","volume":"34","author":"AO von Bueren","year":"2016","unstructured":"von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Muller K et al (2016) Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol 34(34):4151\u20134160","journal-title":"J Clin Oncol"},{"issue":"12","key":"2265_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrclinonc.2014.181","volume":"11","author":"AJ Gajjar","year":"2014","unstructured":"Gajjar AJ, Robinson GW (2014) Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol 11(12):714\u2013722","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2265_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11910-023-01316-9","volume":"23","author":"K Jackson","year":"2023","unstructured":"Jackson K, Packer RJ (2023) Recent advances in pediatric medulloblastoma. Curr Neurol Neurosci Rep 23(12):841\u2013848","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"2265_CR28","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"},{"issue":"9","key":"2265_CR29","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/cancers16091752","volume":"16","author":"KO Holmberg","year":"2024","unstructured":"Holmberg KO, Borgenvik A, Zhao M, Giraud G, Swartling FJ (2024) Drivers underlying metastasis and relapse in medulloblastoma and targeting strategies. Cancers (Basel) 16(9):1752","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2265_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40478-023-01679-7","volume":"11","author":"E Mariotto","year":"2023","unstructured":"Mariotto E, Rampazzo E, Bortolozzi R, Rruga F, Zeni I, Manfreda L et al (2023) Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma. Acta Neuropathol Commun 11(1):183","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"2265_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12031-015-0689-0","volume":"59","author":"A Thomaz","year":"2016","unstructured":"Thomaz A, Jaeger M, Buendia M, Bambini-Junior V, Gregianin LJ, Brunetto AL et al (2016) BDNF\/TrkB signaling as a potential novel target in pediatric brain tumors: anticancer activity of selective TrkB inhibition in medulloblastoma cells. J Mol Neurosci 59(3):326\u2013333","journal-title":"J Mol Neurosci"},{"key":"2265_CR32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3389\/fphar.2019.00698","volume":"10","author":"A Thomaz","year":"2019","unstructured":"Thomaz A, Pinheiro KV, Souza BK, Gregianin L, Brunetto AL, Brunetto AT et al (2019) Antitumor activities and cellular changes induced by TrkB inhibition in medulloblastoma. Front Pharmacol 10:698","journal-title":"Front Pharmacol"},{"key":"2265_CR33","doi-asserted-by":"publisher","first-page":"973912","DOI":"10.1155\/2015\/973912","volume":"2015","author":"C Frasson","year":"2015","unstructured":"Frasson C, Rampazzo E, Accordi B, Beggio G, Pistollato F, Basso G et al (2015) Inhibition of PI3K signalling selectively affects medulloblastoma cancer stem cells. Biomed Res Int 2015:973912","journal-title":"Biomed Res Int"},{"issue":"11","key":"2265_CR34","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/stem.518","volume":"28","author":"F Pistollato","year":"2010","unstructured":"Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L et al (2010) Interaction of hypoxia-inducible factor-1alpha and notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells 28(11):1918\u20131929","journal-title":"Stem Cells"},{"issue":"8","key":"2265_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00018-023-04887-5","volume":"80","author":"M Cescon","year":"2023","unstructured":"Cescon M, Rampazzo E, Bresolin S, Da Ros F, Manfreda L, Cani A et al (2023) Collagen VI sustains cell stemness and chemotherapy resistance in glioblastoma. Cell Mol Life Sci 80(8):233","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2265_CR36","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1002\/cpz1.357","volume":"2","author":"SJ Roper","year":"2022","unstructured":"Roper SJ, Coyle B (2022) Establishing an in vitro 3D spheroid model to study medulloblastoma drug response and tumor dissemination. Curr Protoc 2(1):e357","journal-title":"Curr Protoc"},{"issue":"2","key":"2265_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446","journal-title":"Cancer Res"},{"issue":"12","key":"2265_CR38","doi-asserted-by":"publisher","first-page":"9807","DOI":"10.18632\/oncotarget.3227","volume":"6","author":"L Aubert","year":"2015","unstructured":"Aubert L, Guilbert M, Corbet C, Genot E, Adriaenssens E, Chassat T et al (2015) NGF-induced TrkA\/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib. Oncotarget 6(12):9807\u20139819","journal-title":"Oncotarget"},{"issue":"7","key":"2265_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0024-3205(94)00744-6","volume":"55","author":"K Hayakawa","year":"1994","unstructured":"Hayakawa K, Sobue G, Itoh T, Mitsuma T (1994) Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci 55(7):519\u2013525","journal-title":"Life Sci"},{"issue":"13","key":"2265_CR40","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00018-006-6010-1","volume":"63","author":"JC Arevalo","year":"2006","unstructured":"Arevalo JC, Wu SH (2006) Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci 63(13):1523\u20131537","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"2265_CR41","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00018-016-2156-7","volume":"73","author":"V Chopin","year":"2016","unstructured":"Chopin V, Lagadec C, Toillon RA, Le Bourhis X (2016) Neurotrophin signaling in cancer stem cells. Cell Mol Life Sci 73(9):1859\u20131870","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2265_CR42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1021\/ml200261d","volume":"3","author":"P Albaugh","year":"2012","unstructured":"Albaugh P, Fan Y, Mi Y, Sun F, Adrian F, Li N et al (2012) Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett 3(2):140\u2013145","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"2265_CR43","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.bmcl.2003.12.002","volume":"14","author":"ER Wood","year":"2004","unstructured":"Wood ER, Kuyper L, Petrov KG, Hunter RN III, Harris PA, Lackey K (2004) Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett 14(4):953\u2013957","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"2265_CR44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1530\/ERC-17-0201","volume":"25","author":"ET Aristizabal Prada","year":"2018","unstructured":"Aristizabal Prada ET, Heinzle V, Knosel T, Nolting S, Spottl G, Maurer J et al (2018) Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocr Relat Cancer 25(5):547\u2013560","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2265_CR45","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1177\/0883073815600866","volume":"31","author":"NE Millard","year":"2016","unstructured":"Millard NE, De Braganca KC (2016) Medulloblastoma. J Child Neurol 31(12):1341\u20131353","journal-title":"J Child Neurol"},{"issue":"1","key":"2265_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/neuonc\/nos267","volume":"15","author":"RJ Packer","year":"2013","unstructured":"Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A (2013) Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children\u2019s Oncology Group trial A9961. Neuro Oncol 15(1):97\u2013103","journal-title":"Neuro Oncol"},{"issue":"10","key":"2265_CR47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","volume":"7","author":"A Gajjar","year":"2006","unstructured":"Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE et al (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7(10):813\u2013820","journal-title":"Lancet Oncol"},{"issue":"50","key":"2265_CR48","doi-asserted-by":"publisher","first-page":"eabi5568","DOI":"10.1126\/sciadv.abi5568","volume":"7","author":"D Bakhshinyan","year":"2021","unstructured":"Bakhshinyan D, Adile AA, Liu J, Gwynne WD, Suk Y, Custers S et al (2021) Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence. Sci Adv 7(50):eabi5568","journal-title":"Sci Adv"},{"issue":"8","key":"2265_CR49","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/bjc.2012.391","volume":"107","author":"A Schramm","year":"2012","unstructured":"Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T et al (2012) Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. Br J Cancer 107(8):1409\u20131417","journal-title":"Br J Cancer"},{"issue":"4","key":"2265_CR50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2004.09.011","volume":"6","author":"A Tacconelli","year":"2004","unstructured":"Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A et al (2004) TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6(4):347\u2013360","journal-title":"Cancer Cell"},{"issue":"2","key":"2265_CR51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1523\/JNEUROSCI.17-02-00530.1997","volume":"17","author":"Y Muragaki","year":"1997","unstructured":"Muragaki Y, Chou TT, Kaplan DR, Trojanowski JQ, Lee VM (1997) Nerve growth factor induces apoptosis in human medulloblastoma cell lines that express TrkA receptors. J Neurosci 17(2):530\u2013542","journal-title":"J Neurosci"},{"issue":"2","key":"2265_CR52","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/07357900701205689","volume":"25","author":"A Antonelli","year":"2007","unstructured":"Antonelli A, Lenzi L, Nakagawara A, Osaki T, Chiaretti A, Aloe L (2007) Tumor suppressor proteins are differentially affected in human ependymoblastoma and medulloblastoma cells exposed to nerve growth factor. Cancer Invest 25(2):94\u2013101","journal-title":"Cancer Invest"},{"issue":"5448","key":"2265_CR53","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1126\/science.286.5448.2358","volume":"286","author":"A Riccio","year":"1999","unstructured":"Riccio A, Ahn S, Davenport CM, Blendy JA, Ginty DD (1999) Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286(5448):2358\u20132361","journal-title":"Science"},{"issue":"1\u20132","key":"2265_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11010-019-03518-7","volume":"457","author":"Q Wang","year":"2019","unstructured":"Wang Q, Chen R, Zhang C, Inam UL, Piao F, Shi X (2019) NGF protects bone marrow mesenchymal stem cells against 2,5-hexanedione-induced apoptosis in vitro via Akt\/Bad signal pathway. Mol Cell Biochem 457(1\u20132):133\u2013143","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"2265_CR55","doi-asserted-by":"publisher","first-page":"e94568","DOI":"10.1371\/journal.pone.0094568","volume":"9","author":"P Ruggeri","year":"2014","unstructured":"Ruggeri P, Farina AR, Di Ianni N, Cappabianca L, Ragone M, Ianni G et al (2014) The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD2 expression and activity at the mitochondria, within the context of a tumour stem cell-like phenotype. PLoS ONE 9(4):e94568","journal-title":"PLoS ONE"},{"issue":"2","key":"2265_CR56","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/stem.1849","volume":"33","author":"E Tomellini","year":"2015","unstructured":"Tomellini E, Touil Y, Lagadec C, Julien S, Ostyn P, Ziental-Gelus N et al (2015) Nerve growth factor and proNGF simultaneously promote symmetric self-renewal, quiescence, and epithelial to mesenchymal transition to enlarge the breast cancer stem cell compartment. Stem Cells 33(2):342\u2013353","journal-title":"Stem Cells"},{"issue":"1","key":"2265_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","volume":"5","author":"A Vaishnavi","year":"2015","unstructured":"Vaishnavi A, Le AT, Doebele RC (2015) TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5(1):25\u201334","journal-title":"Cancer Discov"},{"issue":"2","key":"2265_CR58","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","volume":"11","author":"T Jiang","year":"2021","unstructured":"Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J et al (2021) Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm Sin B 11(2):355\u2013372","journal-title":"Acta Pharm Sin B"},{"issue":"Suppl8","key":"2265_CR59","doi-asserted-by":"publisher","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","volume":"30","author":"A Drilon","year":"2019","unstructured":"Drilon A (2019) TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 30(Suppl8):viii23\u2013viii30","journal-title":"Ann Oncol"},{"issue":"8","key":"2265_CR60","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731\u2013739","journal-title":"N Engl J Med"},{"issue":"1","key":"2265_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10555-020-09854-1","volume":"39","author":"O Menyhart","year":"2020","unstructured":"Menyhart O, Gyorffy B (2020) Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. Cancer Metastasis Rev 39(1):211\u2013233","journal-title":"Cancer Metastasis Rev"},{"key":"2265_CR62","doi-asserted-by":"publisher","first-page":"107984","DOI":"10.1016\/j.bioorg.2024.107984","volume":"154","author":"M Malarvannan","year":"2025","unstructured":"Malarvannan M, Unnikrishnan S, Monohar S, Ravichandiran V, Paul D (2025) Design and optimization strategies of PROTACs and its application, comparisons to other targeted protein degradation for multiple oncology therapies. Bioorg Chem 154:107984","journal-title":"Bioorg Chem"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02265-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02265-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02265-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:04:31Z","timestamp":1775225071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02265-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2265"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02265-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HuTuP33 cells were derived from a pediatric MB tumor taken at surgery, as already described in [\n                      \n                      ] under the auspices of the Ethical Committee board of the Padova Academic Hospital. All tissues were acquired following the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}